A number of investment brokers have recently updated their price targets on shares of Life Technologies Corporation (NASDAQ:LIFE). According to the latest broker reports outstanding on Monday 14th of March, 1 analyst has a rating of “strong buy”, 1 analysts “buy”, 1 analysts “neutral”, 0 analysts “sell” and 0 analysts “strong sell”.
Most recent broker ratings
12/16/2015 – Citigroup began new coverage on Life Technologies Corporation giving the company a “neutral” rating.
11/11/2015 – Life Technologies Corporation had its “overweight” rating reiterated by analysts at JP Morgan. They now have a USD 44 price target on the stock.
06/01/2015 – William Blair began new coverage on Life Technologies Corporation giving the company a “outperform” rating. They now have a USD 42 price target on the stock.
06/01/2015 – BMO Capital Markets began new coverage on Life Technologies Corporation giving the company a “outperform” rating. They now have a USD 42 price target on the stock.
01/13/2014 – Life Technologies Corporation was upgraded to “buy” by analysts at Ned Davis Research.
11/20/2013 – Life Technologies Corporation had its “neutral” rating reiterated by analysts at Zacks. They now have a USD 79 price target on the stock.
10/11/2013 – Life Technologies Corporation was downgraded to “hold” by analysts at TheStreet.
The share price of Life Technologies Corporation (NASDAQ:LIFE) was up +0.39% during the last day of trading, with a day high of 5.49. 92108 shares were traded during the last session.
The stock’s 50 day moving average is 4.88 and its 200 day moving average is 9.50. The stock’s market capitalization is 120.60M. Life Technologies Corporation has a 52-week low of 3.50 and a 52-week high of 28.29.
aTyr Pharma, Inc. is a biotherapeutics company. The Company focuses on the discovery and clinical development of medicines for patients suffering from severe, rare diseases using its knowledge of Physiocrine biology, a discovered set of physiological modulators. It focuses on the development of Physiocrine-based therapeutics for the treatment of rare diseases, including facioscapulohumeral muscular dystrophy (FSHD) and limb-girdle muscular dystrophy (LGMD) 2B. The Company’s lead candidate, Resolaris, is an intravenous protein therapeutic for the treatment of myopathies with an immune component. Resolaris is in a Phase Ib/II clinical trial in adult patients with FSHD; a Phase Ib/II trial in adult patients with LGMD 2B or FSHD, and a Phase Ib/II trial in patients with early onset FSHD. As of September 30, 2015, the Company had not generated any revenues.
Source- Risers and fallers
Broad Street Alerts has not been compensated for this post nor do we hold any positions in any securities mentioned above.